BJH - volume 8, issue Abstract Book BHS, february 2017
J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
G. Fransolet , G. Ehx , J. Somja MD, PhD, L. Delens , M. Hannon , S. Dubois , P. Drion , J. Caers MD, PhD, S. Humblet-Baron , L. Belle , P. Delvenne , Y. Beguin MD, PhD, G. Conteduca , prof. F. Baron
BJH - volume 7, issue Abstract Book BHS, january 2016
R. Heusschen PhD, J. Muller MSc, M. Binsfeld , E. Plougonven , N. Mahli , G. Carmeliet , A. Léonard , prof. F. Baron , M. Cohen-Solal , K. Vanderkerken PhD, Y. Beguin MD, PhD, E. Menu , J. Caers MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD
BJH - volume 6, issue 5, december 2015
K. Beel MD, PhD, M.C. Vekemans MD, G. Bries MD, PhD, J. Caers MD, PhD, B. De Pryck MD, K. Fostier MD, A. Kentos MD, PhD, N. Meuleman MD, PhD, P. Mineur MD, I. Van de Broek MD, PhD, K.L. Wu MD, PhD, C. Doyen MD, M. Delforge MD, PhD
Immunoglobulin light chain amyloidosis is a clonal plasma cell dyscrasia, historically associated with a very poor prognosis. Prompt diagnosis is critical to preserve organ function and improve survival in immunoglobulin light chain amyloidosis patients. The severity of cardiac involvement and response to treatment are the most important prognostic factors. Serum free light chain ratio and cardiac biomarkers troponin T and N-terminal pro-brain natriuretic peptide are powerful tools for the evaluation of prognosis and treatment response. Historically, treatment with autologous stem cell transplantation appears to offer a survival benefit, but is only an option in a minority of patients. IMiDs, and especially proteasome inhibitors, have shown promising activity in immunoglobulin light chain amyloidosis. Supportive care should be integrated in the treatment plan and requires a multidisciplinary approach. These guidelines summarise a consensus of the myeloma subcommittee of the Belgian Hematological Society on diagnosis, cytoreductive and supportive treatment of immunoglobulin light chain amyloidosis, based on an extended review of the literature. Where applicable, comments were added with respect to the Belgian reimbursement modalities.
(BELG J HEMATOL 2015;6(5):187–94)
Read moreBJH - volume 6, issue Abstract Book BHS, january 2015
M. Binsfeld , M. Hannon , S. Humblet-Baron , Y. Beguin MD, PhD, prof. F. Baron , J. Caers MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
